Increased Soluble Fibrin in Plasma of Patients with Disseminated Intravascular Coagulation

Abstract

Plasma levels of soluble fibrin (SF) were measured in 1184 patients with disseminated intravascular coagulation (DIC) according to Japanese Ministry of Health and Welfare (JMHW) criteria. The usefulness of SF for the diagnosis of DIC was compared with other hemostatic molecular markers. Most hemostatic markers were significantly increased in patients with DIC than in those without DIC. Plasma levels of fibrin and fibrinogen degradation products, thrombin-antihtrombin complex, plasmin-plasmin inhibitor complex, D-dimer, thrombomodulin, and SF levels were also significantly higher in those with pre-DIC than in those without DIC. In classification of overt DIC by International Society of Thrombosis and Haemostasis (ISTH) criteria, most hemostatic markers were significantly increased in patients with overt DIC than in those without overt DIC. Plasma levels of SF 'in patients with DIC were significantly higher than those in patients with pre-DIC, which were significantly higher than in those without DIC. Plasma levels of SF were also significantly higher in patients with overt DIC than in those with non-overt DIC. The correlation between plasma SF levels and DIC score according to JMHW criteria or ISTH criteria was good. Receiver operating characteristic analysis shows that SF was the best marker for the diagnosis of DIC or overt DIC. These findings suggest that plasma SF might be useful marker for the diagnosis of DIC or overt DIC.

Keywords

SF DIC DIC score ISTH

References

1. Goal HC , Abildgarred U . Gelation of soluble fibrin in plasma by ethanol. Scand J Haematol 1966;3:343-343.

2. Weiding JU , Eisinger G , Kostering H . Determination of soluble fibrin by turbidimetry of its protamine sulphate-induced paracoagulation. J Clin Chem Biochem 1989;27:57-57.

3. Largo R , Heller V , Straub PW . Detection of soluble intermediates of the fibrinogen-fibrin conversion using erythrocytes coated with fibrin monomers. Blood 1976;47:991-991.

4. Nieuwenhuizen W . Soluble fibrin as molecular marker for a prethrombotic state. A mini-review. Blood Coagul Fibrinolysis 1993;4:93-93.

5. Lill H , Spannagl M , Trauner A , et al. A new immunoassay for soluble fibrin enables a more sensitive detection of the activation state of blood coagulation in vivo. Blood Coagul Fibrinolysis 1993;4:97-97.

6. Soe G , Kohno I , Inuzuka K , Itoh Y , Matsuda M . A monoclonal antibody that recognizes a neo-antigen exposed in the E-domain of fibrin monomer complexed with fibrinogen or its derivatives; its application to the measurement of SF in plasma. Blood 1996;88:2109-2109.

7. Wada H , Wakita Y , Nakase T , et al. Increased plasma soluble fibrin monomer levels in patients with disseminated intravascular coagulation. Am J Hematol 1998;51:255-255.

8. Rylatt DB , Blake AS , Cottis LE , et al. An immunoassay for human D-dimer using monoclonal antibodies. Thromb Res 1983;31:767-767.

9. Pelzer H , Schwarz A , Heinburger N . Determination human thrombin-antithrombin III complex in patients with an enzyme-linked immunosorbent assay. Thromb Haemost 1987;59:101-101.

10.

10. Mimuro J , Koike Y , Sumi Y , Aoki N . Monoclonal antibodies to discrete regions in oc2 plasmin inhibitor. Blood 1987; 69:446-446.

11.

11. Wada H , Ohiwa M , Kaneko T , et al. Plasma thrombomodulin as a marker of vascular disorders in thrombotic thrombocytopenic purpura and disseminated intravascular coagulation. Am J Hematol 1992;39:20-20.

12.

12. Bick RL . Disseminated intravascular coagulation and related syndromes: A clinical review. Semin Thromb Hemost 1988; 14:299-299.

13.

13. Muller-Berghaus G . Pathophysiologic and biochemical events in disseminated intravascular coagulation: Dysregulation of procoagulant and anti-coagulant pathways. Semin Thromb Hemost 1989;15:58-58.

14.

14. Kobayashi N , Maegawa K , Takada M , Tanaka H , Gonmori H . Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan. Bibl Haemotol 1987;49:265-265.

15.

15. Members of the American College of Chest Physicians/ Society of Critical Care Medicine, Consensus Conference Committee . Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-864.

16.

16. Beal A , Cerra FB . Multiple organ failure syndrome in the 1990s-systemic inflammatory response and organ dysfunction. JAMA 1994;271:226-226.

17.

17. Bernard GR , Vincent JL , Laterre PF , et al. Efficacy and safety of recombinant human protein C for severe sepsis. N EngI J Med 2001;8:699-699.

18.

18. Waydhas C , Nast-Kolb D , Gippner-Steppert C , et al. Highdose antithrombin III treatment of severely injured patients: Results of a prospective study. J Trauma 1998;45:931-931.

19.

19. Maruyama I . Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation. Thromb Haemost 1999;82:718-718.

20.

20. Abraham E . Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Crit Care Med 2000;28:s31-s31.

21.

21. Taylor Jr FB , Toh CH , Hoots WK , Wada H , Levi M . Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001;86:1327-1327.

22.

22. Wada H , Minamikawa T , Wakita Y , et al. Hemostatic study before onset of disseminated intravascular coagulation. Am J Hematol 1994;43:190-190.

23.

23. Quick AJ , Brown MS , Bancroft FW . A study of the coagulation defect in hemophilia and in jaundice. Am J Med Sci 1935;190:501-501.

24.

24. Hamano A , Tanaka S , Takeda Y , Umeda M , Sakata Y . A novel monoclonal antibody to fibrin monomer and soluble fibrin for the detection of soluble fibrin in plasma. Clin Chim Acta 2002;318:25-25.

25.

25. Goldstein BJ , Mushlin Al . Use of a single thyroxine test to evaluate ambulatory medical patients for suspected hypothyroidism. J Gen Intern Med 1987;2:20-20.

26.

26. Schulman S . Optimal duration of oral anticoagulant therapy in venous thromboembolism. Thromb Haemost 1997; 71:192-192.

27.

27. Wada H , Wakita Y , Nakase T , et al, the Mie DIC study group. Outcome of disseminated intravascular coagulation in relation to the score when treatment was began. Thromb Haemost 1995;74:848-848.